<DOC>
	<DOC>NCT00240344</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.</brief_summary>
	<brief_title>Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>High risk patients High doses of other statins LDLC known, starts with Crestor 10 mg Permission to use patient data by AstraZeneca (AZ)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>High risk patients</keyword>
	<keyword>Crestor</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>LDL cholesterol</keyword>
	<keyword>observational</keyword>
</DOC>